Back to results
US 11,897,876 B2Granted
Isoxazolidines as RIPK1 inhibitors and use thereof
AssigneeGenzyme Corporation
InventorsElisabeth Defossa, Uwe Heinelt, Hans Matter, Maria Mendez-Perez, Nils Rackelmann, Kurt Ritter, Hauke Szillat, Gernot Zech
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
Claims27
A compound of formula I:
- wherein
- A represents a five-membered heteroaryl group in which 2 or 3 ring atoms are independently selected from nitrogen, which is optionally substituted by R3 and R4;
- R1 represents H or CH3,
- R2 represents Cl, F or CN,
- R3 represents H or CH3,
- R4 represents H, CH3 or cyclopropyl,
- R5 represents H or F;
- or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
5 more elements
A compound of formula I:
- wherein
- A represents a five-membered heteroaryl group in which 2 or 3 ring atoms are independently selected from nitrogen, which is optionally substituted by R3 and R4;
- R1 represents H or CH3,
- R2 represents Cl, F or CN,
- R3 represents H or CH3,
- R4 represents H, CH3 or cyclopropyl,
- R5 represents H or F;
- or a pharmaceutically acceptable salt thereof.
5 more elements
Dependencies are inferred from the claim text.